Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The queried entity "RAB9A, member RAS oncogene family pseudogene 2" (abbreviation "RAB9AP2") does not correspond to a recognized protein-coding gene, receptor, enzyme, transporter, or known therapeutic target in major genomic or pharmacological databases. Instead, the described gene appears to be a **pseudogene**, not known to be transcribed or translated into a functional protein; it may be a computational annotation or artifact rather than a genuine functional biomolecule[2][6]. The functional protein relevant to similar nomenclature is **Ras-related protein Rab-9A (RAB9A)**, a small GTPase involved in endosome-to-Golgi transport, but this is distinct from any "pseudogene 2" variant[4][7]. No evidence supports "RAB9AP2" as a receptor, enzyme, or other biological target class in humans or model species. Therefore, this entry should not be considered a valid or actionable therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RAB9A, member RAS oncogene family pseudogene 2 (RAB9AP2).